Anika CEO Joe Darling dies at 62

  • He has been in the position of CEO at Anika for less than two years
  • Responsibilities redistributed
  • Search for a successor

(exechange) — Bedford, Massachusetts, January 29, 2020 — Joe Darling, chief executive of Anika, has died. Anika announced his death on Wednesday, January 29, 2020. Joseph (Joe) Darling has been in the role of Chief Executive Officer at Anika Therapeutics, Inc. for less than two years. He died at age 62.

Anika will undertake a search for a successor.

Following Joe Darling’s death, the position of Chief Executive Officer will not be filled for the time being. Joe Darling’s responsibilities are being redistributed.

“Passed away unexpectedly”

Anika said: “Anika Therapeutics, Inc. (ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62.”

Chaired by Joseph Bower

Anika Therapeutics Inc. is chaired by Joseph Bower.

Joseph Bower has served as the Chair of the Board since March 2018. Bower previously served as lead director when the Board of Directors did not have a Chair.

In the position of CEO since 2018

Joe Darling became CEO of the Company in 2018.

Darling joined Anika as President in July 2017 and was appointed CEO in March 2018, bringing more than 20 years of extensive experience in executive management and leadership from publicly-traded, commercial-stage companies, including Abbott Laboratories, Baxter Healthcare, Smith & Nephew, CONMED, and Wyeth-Ayerst.

Before joining Anika, Darling held executive leadership positions with two small privately held orthopedic companies. Prior to these roles, Darling held senior level executive positions at CONMED Corporation, a global, publicly-held, diversified medical device company, as Global President of its wholly-owned subsidiary, Linvatec Corporation, and as Executive Vice President of Global Corporate Commercial Operations.

At CONMED, Darling led five global business units with approximately $760 million in annual revenues and re-energized the organizational efforts in sales, marketing, R&D, and business development activities that allowed the company to expand its portfolio of product offerings to its customers.

Darling oversaw the launch and commercialization of many key new products while at Linvatec including several new sports medicine technologies in the shoulder (Shoulder Restoration System, Y-Knot Shoulder Anchor line), along with new products in the knee and hip joints.

Before joining CONMED, Darling was Senior Vice President and General Manager for the sports medicine and biologics business at Smith & Nephew, where he played an important role in defining a global strategy that propelled the company to a leadership position in the sports medicine field.

While at Smith & Nephew, Darling and his team were pioneers in developing the Hip Arthroscopy space from a commercial perspective.

Darling launched his career at Abbott Laboratories where he was involved in the commercialization efforts of many pharmaceutical products in the neuroscience, antimicrobial, cardiovascular, and HIV treatment space.

While at Abbott Laboratories, he held management positions in sales and marketing before joining Wyeth-Ayerst Pharmaceuticals in roles of marketing for the pain and inflammation and women’s healthcare franchises.

He later joined Baxter Healthcare as a Vice President of marketing and health systems.

Darling received a Bachelor of Arts in Political Science from Syracuse University.

Push-out Score not determined

When the reason for the departure is death, a Push-out Score™ is not determined.

Read the full story in the exechange report 5.2020 ($).